{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:07:33Z","timestamp":1791400053792,"version":"4.3.3"},"reference-count":131,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2015,6,16]],"date-time":"2015-06-16T00:00:00Z","timestamp":1434412800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,6,16]],"date-time":"2015-06-16T00:00:00Z","timestamp":1434412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1038\/nrrheum.2015.79","type":"journal-article","created":{"date-parts":[[2015,6,16]],"date-time":"2015-06-16T06:21:20Z","timestamp":1434435680000},"page":"573-585","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["From bench to bedside and back again: translational research in autoinflammation"],"prefix":"10.1038","volume":"11","author":[{"given":"Dirk","family":"Holzinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Kessel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Omenetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Gattorno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,6,16]]},"reference":[{"key":"BFnrrheum201579_CR1","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S1074-7613(04)00046-9","volume":"20","author":"L Agostini","year":"2004","unstructured":"Agostini, L.  et al. NALP3 forms an IL-1\u03b2-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 20, 319\u2013325 (2004).","journal-title":"Immunity"},{"key":"BFnrrheum201579_CR2","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/ng756","volume":"29","author":"HM Hoffman","year":"2001","unstructured":"Hoffman, H. M., Mueller, J. L., Broide, D. H., Wanderer, A. A. & Kolodner, R. D. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat. Genet. 29, 301\u2013305 (2001).","journal-title":"Nat. Genet."},{"key":"BFnrrheum201579_CR3","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1056\/NEJMoa055137","volume":"355","author":"R Goldbach-Mansky","year":"2006","unstructured":"Goldbach-Mansky, R.  et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1\u03b2 inhibition. N. Engl. J. Med. 355, 581\u2013592 (2006).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum201579_CR4","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1056\/NEJM200306193482523","volume":"348","author":"PN Hawkins","year":"2003","unstructured":"Hawkins, P. N., Lachmann, H. J. & McDermott, M. F. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N. Engl. J. Med. 348, 2583\u20132584 (2003).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum201579_CR5","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1084\/jem.20050473","volume":"201","author":"V Pascual","year":"2005","unstructured":"Pascual, V., Allantaz, F., Arce, E., Punaro, M. & Banchereau, J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J. Exp. Med. 201, 1479\u20131486 (2005).","journal-title":"J. Exp. Med."},{"key":"BFnrrheum201579_CR6","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.clim.2012.11.008","volume":"147","author":"C Kessel","year":"2013","unstructured":"Kessel, C., Holzinger, D. & Foell, D. Phagocyte-derived S100 proteins in autoinflammation: putative role in pathogenesis and usefulness as biomarkers. Clin. Immunol. 147, 229\u2013241 (2013).","journal-title":"Clin. Immunol."},{"key":"BFnrrheum201579_CR7","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1002\/art.10389","volume":"46","author":"N Maeno","year":"2002","unstructured":"Maeno, N.  et al. Highly elevated serum levels of interleukin-18 in systemic juvenile idiopathic arthritis but not in other juvenile idiopathic arthritis subtypes or in Kawasaki disease: comment on the article by Kawashima  et al. Arthritis Rheum. 46, 2539\u20132541 (2002).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201579_CR8","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1056\/NEJMoa070265","volume":"356","author":"HJ Lachmann","year":"2007","unstructured":"Lachmann, H. J.  et al. Natural history and outcome in systemic AA amyloidosis. N. Engl. J. Med. 356, 2361\u20132371 (2007).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum201579_CR9","doi-asserted-by":"publisher","first-page":"16059","DOI":"10.1073\/pnas.1412487111","volume":"111","author":"W Sha","year":"2014","unstructured":"Sha, W.  et al. Human NLRP3 inflammasome senses multiple types of bacterial RNAs. Proc. Natl Acad. Sci. USA 111, 16059\u201316064 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrrheum201579_CR10","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3389\/fimmu.2013.00333","volume":"4","author":"Y Zhong","year":"2013","unstructured":"Zhong, Y., Kinio, A. & Saleh, M. Functions of NOD-like receptors in human diseases. Front. Immunol. 4, 333 (2013).","journal-title":"Front. Immunol."},{"key":"BFnrrheum201579_CR11","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/rheumatology\/kel346","volume":"46","author":"M Gattorno","year":"2007","unstructured":"Gattorno, M.  et al. Distinct expression pattern of IFN-\u03b1 and TNF-\u03b1 in juvenile idiopathic arthritis synovial tissue. Rheumatology (Oxford) 46, 657\u2013665 (2007).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum201579_CR12","doi-asserted-by":"publisher","first-page":"9789","DOI":"10.1073\/pnas.1000779107","volume":"107","author":"S Tassi","year":"2010","unstructured":"Tassi, S.  et al. Altered redox state of monocytes from cryopyrin-associated periodic syndromes causes accelerated IL-1\u03b2 secretion. Proc. Natl Acad. Sci. USA 107, 9789\u20139794 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrrheum201579_CR13","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1136\/annrheumdis-2012-201340","volume":"71","author":"S Carta","year":"2012","unstructured":"Carta, S.  et al. Deficient production of IL-1 receptor antagonist and IL-6 coupled to oxidative stress in cryopyrin-associated periodic syndrome monocytes. Ann. Rheum. Dis. 71, 1577\u20131581 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201579_CR14","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1056\/NEJMoa0807865","volume":"360","author":"I Aksentijevich","year":"2009","unstructured":"Aksentijevich, I.  et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N. Engl. J. Med. 360, 2426\u20132437 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum201579_CR15","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1056\/NEJMoa1013068","volume":"365","author":"S Marrakchi","year":"2011","unstructured":"Marrakchi, S.  et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N. Engl. J. Med. 365, 620\u2013628 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum201579_CR16","doi-asserted-by":"publisher","first-page":"e1043","DOI":"10.1542\/peds.2012-3935","volume":"132","author":"L Rossi-Semerano","year":"2013","unstructured":"Rossi-Semerano, L.  et al. First clinical description of an infant with interleukin-36-receptor antagonist deficiency successfully treated with anakinra. Pediatrics 132, e1043\u2013e1047 (2013).","journal-title":"Pediatrics"},{"key":"BFnrrheum201579_CR17","doi-asserted-by":"publisher","first-page":"R33","DOI":"10.1186\/ar4184","volume":"15","author":"R Caorsi","year":"2013","unstructured":"Caorsi, R.  et al. The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age. Arthritis Res. Ther. 15, R33 (2013).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum201579_CR18","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/S0140-6736(04)17401-1","volume":"364","author":"HM Hoffman","year":"2004","unstructured":"Hoffman, H. M.  et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 364, 1779\u20131785 (2004).","journal-title":"Lancet"},{"key":"BFnrrheum201579_CR19","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1002\/art.23687","volume":"58","author":"HM Hoffman","year":"2008","unstructured":"Hoffman, H. M.  et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum. 58, 2443\u20132452 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201579_CR20","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1136\/ard.2011.152728","volume":"70","author":"JB Kuemmerle-Deschner","year":"2011","unstructured":"Kuemmerle-Deschner, J. B.  et al. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann. Rheum. Dis. 70, 2095\u20132102 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201579_CR21","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa0810787","volume":"360","author":"HJ Lachmann","year":"2009","unstructured":"Lachmann, H. J.  et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N. Engl. J. Med. 360, 2416\u20132425 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum201579_CR22","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1002\/art.20953","volume":"52","author":"DJ Lovell","year":"2005","unstructured":"Lovell, D. J., Bowyer, S. L. & Solinger, A. M. Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease. Arthritis Rheum. 52, 1283\u20131286 (2005).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201579_CR23","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/j.jaci.2012.07.043","volume":"131","author":"L Kolly","year":"2013","unstructured":"Kolly, L.  et al. Periodic fever, aphthous stomatitis, pharyngitis, cervical adenitis syndrome is linked to dysregulated monocyte IL-1\u03b2 production. J. Allergy Clin. Immunol. 131, 1635\u20131643 (2013).","journal-title":"J. Allergy Clin. Immunol."},{"key":"BFnrrheum201579_CR24","doi-asserted-by":"publisher","first-page":"7148","DOI":"10.1073\/pnas.1103681108","volume":"108","author":"S Stojanov","year":"2011","unstructured":"Stojanov, S.  et al. Periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) is a disorder of innate immunity and TH1 activation responsive to IL-1 blockade. Proc. Natl Acad. Sci. USA 108, 7148\u20137153 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrrheum201579_CR25","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.coi.2014.10.005","volume":"32","author":"YJ Crow","year":"2015","unstructured":"Crow, Y. J. Type I interferonopathies: Mendelian type I interferon up-regulation. Curr. Opin. Immunol. 32, 7\u201312 (2015).","journal-title":"Curr. Opin. Immunol."},{"key":"BFnrrheum201579_CR26","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1312625","volume":"371","author":"Y Liu","year":"2014","unstructured":"Liu, Y.  et al. Activated STING in a vascular and pulmonary syndrome. N. Engl. J. Med. 371, 507\u2013518 (2014).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum201579_CR27","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1136\/ard.2003.014886","volume":"63","author":"G Horneff","year":"2004","unstructured":"Horneff, G.  et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann. Rheum. Dis. 63, 1638\u20131644 (2004).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201579_CR28","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1002\/art.10885","volume":"48","author":"P Quartier","year":"2003","unstructured":"Quartier, P.  et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum. 48, 1093\u20131101 (2003).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201579_CR29","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1084\/jem.20070070","volume":"204","author":"F Allantaz","year":"2007","unstructured":"Allantaz, F.  et al. Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade. J. Exp. Med. 204, 2131\u20132144 (2007).","journal-title":"J. Exp. Med."},{"key":"BFnrrheum201579_CR30","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1002\/art.24601","volume":"60","author":"MG Barnes","year":"2009","unstructured":"Barnes, M. G.  et al. Subtype-specific peripheral blood gene expression profiles in recent-onset juvenile idiopathic arthritis. Arthritis Rheum. 60, 2102\u20132112 (2009).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201579_CR31","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1002\/art.20125","volume":"50","author":"D Foell","year":"2004","unstructured":"Foell, D.  et al. Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations. Arthritis Rheum. 50, 1286\u20131295 (2004).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201579_CR32","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1002\/art.24137","volume":"58","author":"H Wittkowski","year":"2008","unstructured":"Wittkowski, H.  et al. S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. Arthritis Rheum. 58, 3924\u20133931 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201579_CR33","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/art.20946","volume":"52","author":"F de Benedetti","year":"2005","unstructured":"de Benedetti, F. & Martini, A. Targeting the interleukin-6 receptor: a new treatment for systemic juvenile idiopathic arthritis? Arthritis Rheum. 52, 687\u2013693 (2005).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201579_CR34","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1172\/JCI119207","volume":"99","author":"F de Benedetti","year":"1997","unstructured":"de Benedetti, F.  et al. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J. Clin. Invest. 99, 643\u2013650 (1997).","journal-title":"J. Clin. Invest."},{"key":"BFnrrheum201579_CR35","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/S0140-6736(94)91710-8","volume":"344","author":"A Martini","year":"1994","unstructured":"Martini, A.  et al. Intravenous iron therapy for severe anaemia in systemic-onset juvenile chronic arthritis. Lancet 344, 1052\u20131054 (1994).","journal-title":"Lancet"},{"key":"BFnrrheum201579_CR36","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/ejh.12081","volume":"90","author":"G Cangemi","year":"2013","unstructured":"Cangemi, G.  et al. Diagnostic potential of hepcidin testing in pediatrics. Eur. J. Haematol. 90, 323\u2013330 (2013).","journal-title":"Eur. J. Haematol."},{"key":"BFnrrheum201579_CR37","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1172\/JCI200420945","volume":"113","author":"E Nemeth","year":"2004","unstructured":"Nemeth, E.  et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J. Clin. Invest. 113, 1271\u20131276 (2004).","journal-title":"J. Clin. Invest."},{"key":"BFnrrheum201579_CR38","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1002\/art.20944","volume":"52","author":"S Yokota","year":"2005","unstructured":"Yokota, S.  et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 52, 818\u2013825 (2005).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201579_CR39","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","volume":"367","author":"F de Benedetti","year":"2012","unstructured":"de Benedetti, F.  et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N. Engl. J. Med. 367, 2385\u20132395 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum201579_CR40","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1002\/art.23475","volume":"58","author":"M Gattorno","year":"2008","unstructured":"Gattorno, M.  et al. Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum. 58, 1516\u20131520 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201579_CR41","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1002\/art.23437","volume":"58","author":"M Gattorno","year":"2008","unstructured":"Gattorno, M.  et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 58, 1505\u20131515 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201579_CR42","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1136\/ard.2007.076034","volume":"67","author":"T Lequerre","year":"2008","unstructured":"Lequerre, T.  et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann. Rheum. Dis. 67, 302\u2013308 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201579_CR43","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/art.30128","volume":"63","author":"PA Nigrovic","year":"2011","unstructured":"Nigrovic, P. A.  et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 63, 545\u2013555 (2011).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201579_CR44","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1136\/ard.2010.134254","volume":"70","author":"P Quartier","year":"2011","unstructured":"Quartier, P.  et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann. Rheum. Dis. 70, 747\u2013754 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201579_CR45","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/art.38296","volume":"66","author":"SJ Vastert","year":"2014","unstructured":"Vastert, S. J.  et al. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol. 66, 1034\u20131043 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"BFnrrheum201579_CR46","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1002\/art.33342","volume":"64","author":"N Ruperto","year":"2012","unstructured":"Ruperto, N.  et al. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum. 64, 557\u2013567 (2012).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201579_CR47","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","volume":"367","author":"N Ruperto","year":"2012","unstructured":"Ruperto, N.  et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N. Engl. J. Med. 367, 2396\u20132406 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum201579_CR48","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S0092-8674(00)80721-7","volume":"97","author":"MF McDermott","year":"1999","unstructured":"McDermott, M. F.  et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 97, 133\u2013144 (1999).","journal-title":"Cell"},{"key":"BFnrrheum201579_CR49","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1002\/art.33416","volume":"64","author":"AC Bulua","year":"2012","unstructured":"Bulua, A. C.  et al. Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study. Arthritis Rheum. 64, 908\u2013913 (2012).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201579_CR50","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.amjmed.2004.02.039","volume":"117","author":"A Simon","year":"2004","unstructured":"Simon, A.  et al. Beneficial response to interleukin 1 receptor antagonist in TRAPS. Am. J. Med. 117, 208\u2013210 (2004).","journal-title":"Am. J. Med."},{"key":"BFnrrheum201579_CR51","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1136\/annrheumdis-2011-201268","volume":"72","author":"N Ter Haar","year":"2013","unstructured":"Ter Haar, N.  et al. Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann. Rheum. Dis. 72, 678\u2013685 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201579_CR52","doi-asserted-by":"publisher","first-page":"907","DOI":"10.7326\/0003-4819-156-12-201206190-00027","volume":"156","author":"MG Brizi","year":"2012","unstructured":"Brizi, M. G., Galeazzi, M., Lucherini, O. M., Cantarini, L. & Cimaz, R. Successful treatment of tumor necrosis factor receptor-associated periodic syndrome with canakinumab. Ann. Intern. Med. 156, 907\u2013908 (2012).","journal-title":"Ann. Intern. Med."},{"key":"BFnrrheum201579_CR53","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1084\/jem.20102049","volume":"208","author":"AC Bulua","year":"2011","unstructured":"Bulua, A. C.  et al. Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS). J. Exp. Med. 208, 519\u2013533 (2011).","journal-title":"J. Exp. Med."},{"key":"BFnrrheum201579_CR54","doi-asserted-by":"publisher","first-page":"9801","DOI":"10.1073\/pnas.0914118107","volume":"107","author":"A Simon","year":"2010","unstructured":"Simon, A.  et al. Concerted action of wild-type and mutant TNF receptors enhances inflammation in TNF receptor 1-associated periodic fever syndrome. Proc. Natl Acad. Sci. USA 107, 9801\u20139806 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrrheum201579_CR55","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1136\/annrheumdis-2011-201197","volume":"71","author":"LJ Dickie","year":"2012","unstructured":"Dickie, L. J.  et al. Involvement of X-box binding protein 1 and reactive oxygen species pathways in the pathogenesis of tumour necrosis factor receptor-associated periodic syndrome. Ann. Rheum. Dis. 71, 2035\u20132043 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201579_CR56","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.it.2011.08.005","volume":"32","author":"A Rubartelli","year":"2011","unstructured":"Rubartelli, A., Gattorno, M., Netea, M. G. & Dinarello, C. A. Interplay between redox status and inflammasome activation. Trends Immunol. 32, 559\u2013566 (2011).","journal-title":"Trends Immunol."},{"key":"BFnrrheum201579_CR57","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1136\/annrheumdis-2012-201952","volume":"72","author":"T Bachetti","year":"2013","unstructured":"Bachetti, T.  et al. Autophagy contributes to inflammation in patients with TNFR-associated periodic syndrome (TRAPS). Ann. Rheum. Dis. 72, 1044\u20131052 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201579_CR58","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1002\/art.10550","volume":"46","author":"J Frenkel","year":"2002","unstructured":"Frenkel, J.  et al. Lack of isoprenoid products raises ex vivo interleukin-1\u03b2 secretion in hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum. 46, 2794\u20132803 (2002).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201579_CR59","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/ni.1980","volume":"12","author":"K Nakahira","year":"2011","unstructured":"Nakahira, K.  et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat. Immunol. 12, 222\u2013230 (2011).","journal-title":"Nat. Immunol."},{"key":"BFnrrheum201579_CR60","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1002\/art.24298","volume":"60","author":"N Knowlton","year":"2009","unstructured":"Knowlton, N.  et al. The meaning of clinical remission in polyarticular juvenile idiopathic arthritis: gene expression profiling in peripheral blood mononuclear cells identifies distinct disease states. Arthritis Rheum. 60, 892\u2013900 (2009).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201579_CR61","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1164\/rccm.201209-1602OC","volume":"187","author":"D Foell","year":"2013","unstructured":"Foell, D.  et al. Proinflammatory S100A12 can activate human monocytes via Toll-like receptor 4. Am. J. Respir. Crit. Care Med. 187, 1324\u20131334 (2013).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"BFnrrheum201579_CR62","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/nm1638","volume":"13","author":"T Vogl","year":"2007","unstructured":"Vogl, T.  et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat. Med. 13, 1042\u20131049 (2007).","journal-title":"Nat. Med."},{"key":"BFnrrheum201579_CR63","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/art.24349","volume":"60","author":"M Frosch","year":"2009","unstructured":"Frosch, M.  et al. The myeloid-related proteins 8 and 14 complex, a novel ligand of Toll-like receptor 4, and interleukin-1\u03b2 form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 60, 883\u2013891 (2009).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201579_CR64","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1136\/ard.2009.114363","volume":"69","author":"T Kallinich","year":"2010","unstructured":"Kallinich, T., Wittkowski, H., Keitzer, R., Roth, J. & Foell, D. Neutrophil-derived S100A12 as novel biomarker of inflammation in familial Mediterranean fever. Ann. Rheum. Dis. 69, 677\u2013682 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201579_CR65","doi-asserted-by":"publisher","first-page":"4415","DOI":"10.1002\/pmic.201000298","volume":"10","author":"XB Ling","year":"2010","unstructured":"Ling, X. B.  et al. Plasma profiles in active systemic juvenile idiopathic arthritis: biomarkers and biological implications. Proteomics 10, 4415\u20134430 (2010).","journal-title":"Proteomics"},{"key":"BFnrrheum201579_CR66","doi-asserted-by":"publisher","first-page":"4174","DOI":"10.1002\/art.23042","volume":"56","author":"H Wittkowski","year":"2007","unstructured":"Wittkowski, H.  et al. Acute Kawasaki disease is associated with reverse regulation of soluble receptor for advance glycation end products and its proinflammatory ligand S100A12. Arthritis Rheum. 56, 4174\u20134181 (2007).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201579_CR67","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1136\/ard.2011.152496","volume":"70","author":"H Wittkowski","year":"2011","unstructured":"Wittkowski, H.  et al. MRP8 and MRP14, phagocyte-specific danger signals, are sensitive biomarkers of disease activity in cryopyrin-associated periodic syndromes. Ann. Rheum. Dis. 70, 2075\u20132081 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201579_CR68","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1136\/annrheumdis-2011-200598","volume":"71","author":"D Holzinger","year":"2012","unstructured":"Holzinger, D.  et al. The Toll-like receptor 4 agonist MRP8\/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis. Ann. Rheum. Dis. 71, 974\u2013980 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201579_CR69","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1093\/rheumatology\/ket152","volume":"52","author":"H Moncrieffe","year":"2013","unstructured":"Moncrieffe, H.  et al. A subgroup of juvenile idiopathic arthritis patients who respond well to methotrexate are identified by the serum biomarker MRP8\/14 protein. Rheumatology (Oxford) 52, 1467\u20131476 (2013).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum201579_CR70","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/jama.2010.375","volume":"303","author":"D Foell","year":"2010","unstructured":"Foell, D.  et al. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA 303, 1266\u20131273 (2010).","journal-title":"JAMA"},{"key":"BFnrrheum201579_CR71","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1136\/annrheumdis-2012-201329","volume":"71","author":"J Gerss","year":"2012","unstructured":"Gerss, J.  et al. Phagocyte-specific S100 proteins and high-sensitivity C reactive protein as biomarkers for a risk-adapted treatment to maintain remission in juvenile idiopathic arthritis: a comparative study. Ann. Rheum. Dis. 71, 1991\u20131997 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201579_CR72","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1002\/acr.22248","volume":"66","author":"F Rothmund","year":"2014","unstructured":"Rothmund, F.  et al. Validation of relapse risk biomarkers for routine use in patients with juvenile idiopathic arthritis. Arthritis Care Res. (Hoboken) 66, 949\u2013955 (2014).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"BFnrrheum201579_CR73","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.semnephrol.2006.09.013","volume":"27","author":"CA Dinarello","year":"2007","unstructured":"Dinarello, C. A. Interleukin-18 and the pathogenesis of inflammatory diseases. Semin. Nephrol. 27, 98\u2013114 (2007).","journal-title":"Semin. Nephrol."},{"key":"BFnrrheum201579_CR74","first-page":"483","volume":"11","author":"CA Dinarello","year":"2000","unstructured":"Dinarello, C. A. Interleukin-18, a proinflammatory cytokine. Eur. Cytokine Netw. 11, 483\u2013486 (2000).","journal-title":"Eur. Cytokine Netw."},{"key":"BFnrrheum201579_CR75","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S0091-6749(99)70518-X","volume":"103","author":"CA Dinarello","year":"1999","unstructured":"Dinarello, C. A. IL-18: a TH1-inducing, proinflammatory cytokine and new member of the IL-1 family. J. Allergy Clin. Immunol. 103, 11\u201324 (1999).","journal-title":"J. Allergy Clin. Immunol."},{"key":"BFnrrheum201579_CR76","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.4049\/jimmunol.167.5.2879","volume":"167","author":"BP Leung","year":"2001","unstructured":"Leung, B. P.  et al. A role for IL-18 in neutrophil activation. J. Immunol. 167, 2879\u20132886 (2001).","journal-title":"J. Immunol."},{"key":"BFnrrheum201579_CR77","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/jlb.63.6.658","volume":"63","author":"CA Dinarello","year":"1998","unstructured":"Dinarello, C. A.  et al. Overview of interleukin-18: more than an interferon-\u03b3 inducing factor. J. Leukoc. Biol. 63, 658\u2013664 (1998).","journal-title":"J. Leukoc. Biol."},{"key":"BFnrrheum201579_CR78","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1007\/s10067-006-0474-0","volume":"26","author":"M Jelusic","year":"2007","unstructured":"Jelusic, M.  et al. Interleukin-18 as a mediator of systemic juvenile idiopathic arthritis. Clin. Rheumatol. 26, 1332\u20131334 (2007).","journal-title":"Clin. Rheumatol."},{"key":"BFnrrheum201579_CR79","first-page":"823","volume":"34","author":"AP Lotito","year":"2007","unstructured":"Lotito, A. P., Campa, A., Silva, C. A., Kiss, M. H. & Mello, S. B. Interleukin 18 as a marker of disease activity and severity in patients with juvenile idiopathic arthritis. J. Rheumatol. 34, 823\u2013830 (2007).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum201579_CR80","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.cyto.2012.11.025","volume":"61","author":"M Shimizu","year":"2013","unstructured":"Shimizu, M., Nakagishi, Y. & Yachie, A. Distinct subsets of patients with systemic juvenile idiopathic arthritis based on their cytokine profiles. Cytokine 61, 345\u2013348 (2013).","journal-title":"Cytokine"},{"key":"BFnrrheum201579_CR81","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1182\/blood-2005-05-1980","volume":"106","author":"K Mazodier","year":"2005","unstructured":"Mazodier, K.  et al. Severe imbalance of IL-18\/IL-18BP in patients with secondary hemophagocytic syndrome. Blood 106, 3483\u20133489 (2005).","journal-title":"Blood"},{"key":"BFnrrheum201579_CR82","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1093\/rheumatology\/keq133","volume":"49","author":"M Shimizu","year":"2010","unstructured":"Shimizu, M.  et al. Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis. Rheumatology (Oxford) 49, 1645\u20131653 (2010).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum201579_CR83","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s100670050068","volume":"18","author":"K Laiho","year":"1999","unstructured":"Laiho, K., Tiitinen, S., Kaarela, K., Helin, H. & Isomaki, H. Secondary amyloidosis has decreased in patients with inflammatory joint disease in Finland. Clin. Rheumatol. 18, 122\u2013123 (1999).","journal-title":"Clin. Rheumatol."},{"key":"BFnrrheum201579_CR84","first-page":"371","volume":"34","author":"G Singh","year":"2007","unstructured":"Singh, G., Kumari, N., Aggarwal, A., Krishnani, N. & Misra, R. Prevalence of subclinical amyloidosis in ankylosing spondylitis. J. Rheumatol. 34, 371\u2013373 (2007).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum201579_CR85","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1021\/bi00257a008","volume":"21","author":"DC Parmelee","year":"1982","unstructured":"Parmelee, D. C.  et al. Amino acid sequence of amyloid-related apoprotein (apoSAA1) from human high-density lipoprotein. Biochemistry 21, 3298\u20133303 (1982).","journal-title":"Biochemistry"},{"key":"BFnrrheum201579_CR86","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/00062752-200001000-00012","volume":"7","author":"S Urieli-Shoval","year":"2000","unstructured":"Urieli-Shoval, S., Linke, R. P. & Matzner, Y. Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr. Opin. Hematol. 7, 64\u201369 (2000).","journal-title":"Curr. Opin. Hematol."},{"key":"BFnrrheum201579_CR87","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1056\/NEJMra023144","volume":"349","author":"G Merlini","year":"2003","unstructured":"Merlini, G. & Bellotti, V. Molecular mechanisms of amyloidosis. N. Engl. J. Med. 349, 583\u2013596 (2003).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum201579_CR88","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev.med.57.121304.131243","volume":"57","author":"MB Pepys","year":"2006","unstructured":"Pepys, M. B. Amyloidosis. Annu. Rev. Med. 57, 223\u2013241 (2006).","journal-title":"Annu. Rev. Med."},{"key":"BFnrrheum201579_CR89","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1002\/art.37827","volume":"65","author":"T Lane","year":"2013","unstructured":"Lane, T.  et al. AA amyloidosis complicating the hereditary periodic fever syndromes. Arthritis Rheum 65, 1116\u201321 (2013).","journal-title":"Arthritis Rheum"},{"key":"BFnrrheum201579_CR90","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1136\/annrheumdis-2014-206424","volume":"74","author":"T van den Broek","year":"2015","unstructured":"van den Broek, T.  et al. Cytokine profiling at disease onset: support for classification of young antinuclear antibody-positive patients as a separate category of juvenile idiopathic arthritis. Ann. Rheum. Dis. 74, 470\u2013472 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201579_CR91","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1136\/annrheumdis-2012-202082","volume":"72","author":"JE Balow Jr","year":"2013","unstructured":"Balow, J. E. Jr  et al. Microarray-based gene expression profiling in patients with cryopyrin-associated periodic syndromes defines a disease-related signature and IL-1-responsive transcripts. Ann. Rheum. Dis. 72, 1064\u20131070 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201579_CR92","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1002\/eji.201344328","volume":"44","author":"OH Negm","year":"2014","unstructured":"Negm, O. H.  et al. A pro-inflammatory signalome is constitutively activated by C33Y mutant TNF receptor 1 in TNF receptor-associated periodic syndrome (TRAPS). Eur. J. Immunol. 44, 2096\u20132110 (2014).","journal-title":"Eur. J. Immunol."},{"key":"BFnrrheum201579_CR93","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.coi.2013.08.005","volume":"25","author":"R Banchereau","year":"2013","unstructured":"Banchereau, R., Cepika, A. M. & Pascual, V. Systems approaches to human autoimmune diseases. Curr. Opin. Immunol. 25, 598\u2013605 (2013).","journal-title":"Curr. Opin. Immunol."},{"key":"BFnrrheum201579_CR94","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1038\/ng.3089","volume":"46","author":"SW Canna","year":"2014","unstructured":"Canna, S. W.  et al. An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nat. Genet. 46, 1140\u20131146 (2014).","journal-title":"Nat. Genet."},{"key":"BFnrrheum201579_CR95","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1002\/art.24750","volume":"60","author":"W de Jager","year":"2009","unstructured":"de Jager, W.  et al. Defective phosphorylation of interleukin-18 receptor \u03b2 causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 60, 2782\u20132793 (2009).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201579_CR96","doi-asserted-by":"publisher","first-page":"R30","DOI":"10.1186\/ar1453","volume":"7","author":"J Villanueva","year":"2005","unstructured":"Villanueva, J.  et al. Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. Arthritis Res. Ther. 7, R30\u2013R37 (2005).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum201579_CR97","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1067\/mpd.2003.110","volume":"142","author":"AA Grom","year":"2003","unstructured":"Grom, A. A.  et al. Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J. Pediatr. 142, 292\u2013296 (2003).","journal-title":"J. Pediatr."},{"key":"BFnrrheum201579_CR98","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1002\/art.38793","volume":"66","author":"KM Kaufman","year":"2014","unstructured":"Kaufman, K. M.  et al. Whole exome sequencing reveals overlap between macrophage activation syndrome in systemic juvenile idiopathic arthritis and familial hemophagocytic lymphohistiocytosis. Arthritis Rheumatol. 66, 3486\u20133495 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"BFnrrheum201579_CR99","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.clim.2015.01.003","volume":"157","author":"N Rieber","year":"2015","unstructured":"Rieber, N.  et al. A functional inflammasome activation assay differentiates patients with pathogenic NLRP3 mutations and symptomatic patients with low penetrance variants. Clin. Immunol. 157, 56\u201364 (2015).","journal-title":"Clin. Immunol."},{"key":"BFnrrheum201579_CR100","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1111\/cei.12361","volume":"177","author":"MH Haverkamp","year":"2014","unstructured":"Haverkamp, M. H., van de Vosse, E., Goldbach-Mansky, R. & Holland, S. M. Impaired cytokine responses in patients with cryopyrin-associated periodic syndrome (CAPS). Clin. Exp. Immunol. 177, 720\u2013731 (2014).","journal-title":"Clin. Exp. Immunol."},{"key":"BFnrrheum201579_CR101","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1136\/annrheumdis-2012-202774","volume":"73","author":"A Omenetti","year":"2014","unstructured":"Omenetti, A.  et al. Increased NLRP3-dependent interleukin 1\u03b2 secretion in patients with familial Mediterranean fever: correlation with MEFV genotype. Ann. Rheum. Dis. 73, 462\u2013469 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201579_CR102","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1189\/jlb.0512265","volume":"92","author":"A Rubartelli","year":"2012","unstructured":"Rubartelli, A. Redox control of NLRP3 inflammasome activation in health and disease. J. Leukoc. Biol. 92, 951\u2013958 (2012).","journal-title":"J. Leukoc. Biol."},{"key":"BFnrrheum201579_CR103","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1084\/jem.20141091","volume":"211","author":"A Kitamura","year":"2014","unstructured":"Kitamura, A., Sasaki, Y., Abe, T., Kano, H. & Yasutomo, K. An inherited mutation in NLRC4 causes autoinflammation in human and mice. J. Exp. Med. 211, 2385\u20132396 (2014).","journal-title":"J. Exp. Med."},{"key":"BFnrrheum201579_CR104","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1002\/art.38359","volume":"66","author":"A Avau","year":"2014","unstructured":"Avau, A.  et al. Systemic juvenile idiopathic arthritis-like syndrome in mice following stimulation of the immune system with Freund's complete adjuvant: regulation by interferon-gamma. Arthritis Rheumatol. 66, 1340\u20131351 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"BFnrrheum201579_CR105","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1172\/JCI43157","volume":"121","author":"EM Behrens","year":"2011","unstructured":"Behrens, E. M.  et al. Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice. J. Clin. Invest. 121, 2264\u20132277 (2011).","journal-title":"J. Clin. Invest."},{"key":"BFnrrheum201579_CR106","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.immuni.2013.08.009","volume":"39","author":"Y Qiao","year":"2013","unstructured":"Qiao, Y.  et al. Synergistic activation of inflammatory cytokine genes by interferon-\u03b3-induced chromatin remodeling and Toll-like receptor signaling. Immunity 39, 454\u2013469 (2013).","journal-title":"Immunity"},{"key":"BFnrrheum201579_CR107","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/j.celrep.2014.08.023","volume":"8","author":"T Yoshitaka","year":"2014","unstructured":"Yoshitaka, T.  et al. Enhanced TLR\u2013MYD88 signaling stimulates autoinflammation in SH3BP2 cherubism mice and defines the etiology of cherubism. Cell Rep. 8, 1752\u20131766 (2014).","journal-title":"Cell Rep."},{"key":"BFnrrheum201579_CR108","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1084\/jem.20120189","volume":"209","author":"E Venereau","year":"2012","unstructured":"Venereau, E.  et al. Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J. Exp. Med. 209, 1519\u20131528 (2012).","journal-title":"J. Exp. Med."},{"key":"BFnrrheum201579_CR109","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/art.33368","volume":"64","author":"Y Liu","year":"2012","unstructured":"Liu, Y.  et al. Mutations in proteasome subunit \u03b2 type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity. Arthritis Rheum. 64, 895\u2013907 (2012).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201579_CR110","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/nature10957","volume":"484","author":"CE Zielinski","year":"2012","unstructured":"Zielinski, C. E.  et al. Pathogen-induced human TH17 cells produce IFN-\u03b3 or IL-10 and are regulated by IL-1\u03b2. Nature 484, 514\u2013518 (2012).","journal-title":"Nature"},{"key":"BFnrrheum201579_CR111","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3899\/jrheum.100726","volume":"38","author":"JL Record","year":"2011","unstructured":"Record, J. L., Beukelman, T. & Cron, R. Q. Combination therapy of abatacept and anakinra in children with refractory systemic juvenile idiopathic arthritis: a retrospective case series. J. Rheumatol. 38, 180\u2013181 (2011).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum201579_CR112","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1002\/art.38615","volume":"66","author":"PA Nigrovic","year":"2014","unstructured":"Nigrovic, P. A. Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis? Arthritis Rheumatol. 66, 1405\u20131413 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"BFnrrheum201579_CR113","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nature04516","volume":"440","author":"F Martinon","year":"2006","unstructured":"Martinon, F., Petrilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237\u2013241 (2006).","journal-title":"Nature"},{"key":"BFnrrheum201579_CR114","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.1002\/art.27600","volume":"62","author":"A So","year":"2010","unstructured":"So, A.  et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum. 62, 3064\u20133076 (2010).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201579_CR115","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nature11588","volume":"492","author":"GS Lee","year":"2012","unstructured":"Lee, G. S.  et al. The calcium-sensing receptor regulates the NLRP3 inflammasome through Ca2+ and cAMP. Nature 492, 123\u2013127 (2012).","journal-title":"Nature"},{"key":"BFnrrheum201579_CR116","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1038\/sj.cdd.4402142","volume":"14","author":"S Papin","year":"2007","unstructured":"Papin, S.  et al. The SPRY domain of Pyrin, mutated in familial Mediterranean fever patients, interacts with inflammasome components and inhibits proIL-1\u03b2 processing. Cell Death. Differ. 14, 1457\u20131466 (2007).","journal-title":"Cell Death. Differ."},{"key":"BFnrrheum201579_CR117","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.immuni.2011.02.020","volume":"34","author":"JJ Chae","year":"2011","unstructured":"Chae, J. J.  et al. Gain-of-function pyrin mutations induce NLRP3 protein-independent interleukin-1\u03b2 activation and severe autoinflammation in mice. Immunity 34, 755\u2013768 (2011).","journal-title":"Immunity"},{"key":"BFnrrheum201579_CR118","doi-asserted-by":"publisher","first-page":"9982","DOI":"10.1073\/pnas.0602081103","volume":"103","author":"JJ Chae","year":"2006","unstructured":"Chae, J. J.  et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1\u03b2 production. Proc. Natl Acad. Sci. USA 103, 9982\u20139987 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrrheum201579_CR119","doi-asserted-by":"publisher","first-page":"13501","DOI":"10.1073\/pnas.2135380100","volume":"100","author":"NG Shoham","year":"2003","unstructured":"Shoham, N. G.  et al. Pyrin binds the PSTPIP1\/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc. Natl Acad. Sci. USA 100, 13501\u201313506 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrrheum201579_CR120","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1002\/art.27521","volume":"62","author":"CL Cortesio","year":"2010","unstructured":"Cortesio, C. L., Wernimont, S. A., Kastner, D. L., Cooper, K. M. & Huttenlocher, A. Impaired podosome formation and invasive migration of macrophages from patients with a PSTPIP1 mutation and PAPA syndrome. Arthritis Rheum. 62, 2556\u20132558 (2010).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201579_CR121","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1073\/pnas.0708616105","volume":"105","author":"I Jeru","year":"2008","unstructured":"Jeru, I.  et al. Mutations in NALP12 cause hereditary periodic fever syndromes. Proc. Natl Acad. Sci. USA 105, 1614\u20131619 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrrheum201579_CR122","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1002\/art.30170","volume":"63","author":"S Borghini","year":"2011","unstructured":"Borghini, S.  et al. Clinical presentation and pathogenesis of cold-induced autoinflammatory disease in a family with recurrence of an NLRP12 mutation. Arthritis Rheum. 63, 830\u2013839 (2011).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201579_CR123","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1002\/art.21657","volume":"54","author":"A D'Osualdo","year":"2006","unstructured":"D'Osualdo, A.  et al. Neutrophils from patients with TNFRSF1A mutations display resistance to tumor necrosis factor-induced apoptosis: pathogenetic and clinical implications. Arthritis Rheum 54, 998\u20131008 (2006).","journal-title":"Arthritis Rheum"},{"key":"BFnrrheum201579_CR124","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/art.23123","volume":"58","author":"B Nedjai","year":"2008","unstructured":"Nedjai, B.  et al. Abnormal tumor necrosis factor receptor I cell surface expression and NF-\u03baB activation in tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum. 58, 273\u2013283 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201579_CR125","doi-asserted-by":"publisher","first-page":"27757","DOI":"10.1074\/jbc.M114.571810","volume":"289","author":"R van der Burgh","year":"2014","unstructured":"van der Burgh, R.  et al. Unprenylated RhoA contributes to IL-1\u03b2 hypersecretion in mevalonate kinase deficiency model through stimulation of Rac1 activity. J. Biol. Chem. 289, 27757\u201327765 (2014).","journal-title":"J. Biol. Chem."},{"key":"BFnrrheum201579_CR126","doi-asserted-by":"publisher","first-page":"5000","DOI":"10.1074\/jbc.M113.536920","volume":"289","author":"R van der Burgh","year":"2014","unstructured":"van der Burgh, R.  et al. Defects in mitochondrial clearance predispose human monocytes to interleukin-1beta hypersecretion. J. Biol. Chem. 289, 5000\u20135012 (2014).","journal-title":"J. Biol. Chem."},{"key":"BFnrrheum201579_CR127","doi-asserted-by":"publisher","first-page":"10894","DOI":"10.1074\/jbc.M112.342915","volume":"287","author":"M Valdearcos","year":"2012","unstructured":"Valdearcos, M.  et al. Lipin-2 reduces proinflammatory signaling induced by saturated fatty acids in macrophages. J. Biol. Chem. 287, 10894\u201310904 (2012).","journal-title":"J. Biol. Chem."},{"key":"BFnrrheum201579_CR128","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1056\/NEJMoa0907206","volume":"361","author":"EO Glocker","year":"2009","unstructured":"Glocker, E. O.  et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N. Engl. J. Med. 361, 2033\u20132045 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum201579_CR129","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1182\/blood-2004-07-2972","volume":"105","author":"N Kanazawa","year":"2005","unstructured":"Kanazawa, N.  et al. Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-\u03baB activation: common genetic etiology with Blau syndrome. Blood 105, 1195\u20131197 (2005).","journal-title":"Blood"},{"key":"BFnrrheum201579_CR130","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.ajhg.2012.03.012","volume":"90","author":"CT Jordan","year":"2012","unstructured":"Jordan, C. T.  et al. PSORS2 is due to mutations in CARD14. Am. J. Hum. Genet. 90, 784\u2013795 (2012).","journal-title":"Am. J. Hum. Genet."},{"key":"BFnrrheum201579_CR131","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa1307361","volume":"370","author":"Q Zhou","year":"2014","unstructured":"Zhou, Q.  et al. Early-onset stroke and vasculopathy associated with mutations in ADA2. N. Engl. J. Med. 370, 911\u2013920 (2014).","journal-title":"N. Engl. J. Med."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/nrrheum.2015.79.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrrheum.2015.79","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrrheum.2015.79.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T19:19:30Z","timestamp":1650050370000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrrheum.2015.79"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,16]]},"references-count":131,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["BFnrrheum201579"],"URL":"https:\/\/doi.org\/10.1038\/nrrheum.2015.79","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,16]]},"assertion":[{"value":"16 June 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.H. declares that he has received speaker's fees from Novartis. M.G. declares that he has received speaker's and consultancy fees from Novartis and SOBI. C.K. and A.O. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}